| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (NCT05335993) | CanariaBio Inc. | 2022-07-25 |
| Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer (NCT05406674) | The Netherlands Cancer Institute | 2022-06-15 |
| Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases (NCT05353582) | Sun Yat-sen University | 2022-06-01 |
| BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei (NCT03976973) | Mucpharm Pty Ltd | 2022-05-01 |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors (NCT05080946) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-02 |
| Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (NCT05041257) | AbbVie | 2021-10-19 |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (NCT04907643) | Cedars-Sinai Medical Center | 2021-10-05 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC (NCT04983550) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-09-01 |
| A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04846842) | Lee's Pharmaceutical Limited | 2021-07-01 |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer (NCT04611126) | Inge Marie Svane | 2021-04-22 |
| Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI) (NCT05718726) | Hampshire Hospitals NHS Foundation Trust | 2021-03-25 |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (NCT04676334) | pharmaand GmbH | 2021-03-22 |
| Tempus Priority Study: A Pan-tumor Observational Study (NCT05179824) | Tempus AI | 2020-10-19 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (NCT04498117) | CanariaBio Inc. | 2020-08-25 |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (NCT04296890) | ImmunoGen, Inc. | 2020-07-23 |
| Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival (NCT04402333) | Royal Surrey County Hospital NHS Foundation Trust | 2020-06-26 |
| Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR (NCT04295577) | Royal Marsden NHS Foundation Trust | 2020-02-03 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression (NCT04209855) | AbbVie | 2019-12-31 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors (NCT03023319) | Nagla Abdel Karim | 2019-12-10 |
| Genomic BRCA and Extensive ovArian Cancer Testing (NCT04027868) | ARCAGY/ GINECO GROUP | 2019-12-06 |
| Phase I Trial HIPEC With Nal-irinotecan (NCT04088786) | Stony Brook University | 2019-10-22 |
| Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis (NCT04122885) | University Hospital Tuebingen | 2019-10-01 |
| Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients (NCT04537702) | Duke University | 2019-08-08 |
| A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum (NCT04022213) | Memorial Sloan Kettering Cancer Center | 2019-07-15 |
| Detecting Activity to Support Healing (NCT03211806) | University of Pittsburgh | 2019-06-06 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (NCT03430700) | University College, London | 2019-05-16 |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) (NCT03657043) | Seagen Inc. | 2019-03-20 |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer (NCT03693248) | Seoul National University Hospital | 2018-12-19 |
| Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn) (NCT06599749) | University Hospital, Basel, Switzerland | 2018-12-01 |
| Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway (NCT03359811) | M.D. Anderson Cancer Center | 2017-11-27 |
| Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer (NCT03126812) | The Netherlands Cancer Institute | 2017-11-01 |
| Real-life Use of Niraparib in a Patient Access Program in Norway (NCT04785716) | Kristina Lindemann | 2017-07-31 |
| Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (NCT02758951) | Koen Rovers | 2017-06-01 |
| Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer (NCT02915523) | Syndax Pharmaceuticals | 2016-12-19 |
| A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib (NCT02873962) | Dana-Farber Cancer Institute | 2016-11-10 |
| Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer (NCT02973750) | H. Lee Moffitt Cancer Center and Research Institute | 2016-10-20 |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer (NCT02865811) | Dana-Farber Cancer Institute | 2016-09-15 |
| HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma (NCT02487849) | Krankenhaus Barmherzige Schwestern Linz | 2016-08-01 |
| A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers (NCT02728830) | AA Secord | 2016-06-01 |
| A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers (NCT02824328) | Duke University | 2016-06-01 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer (NCT02668913) | Geoff Hall | 2016-02-01 |
| Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer (NCT02534922) | Oncolix, Inc. | 2016-02-01 |
| A Study of Long-Term Responders on Olaparib (NCT02489058) | University Health Network, Toronto | 2016-02-01 |
| Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (NCT02741167) | University of Zurich | 2016-01-01 |
| Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (NCT02433626) | Critical Outcome Technologies Inc. | 2015-12-01 |
| Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients (NCT02470299) | New Mexico Cancer Research Alliance | 2015-10-29 |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (NCT01968213) | pharmaand GmbH | 2014-04-07 |
| The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (NCT01556841) | University College, London | 2013-11-01 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (NCT01891344) | pharmaand GmbH | 2013-10-30 |
| Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer (NCT03332576) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2013-08-23 |
| BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer (NCT01669798) | AA Secord | 2013-02-01 |
| Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01767675) | Memorial Sloan Kettering Cancer Center | 2013-01-08 |
| Accelerating Gastrointestinal Recovery (NCT01704651) | Jamie N. Bakkum-Gamez | 2013-01-01 |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer (NCT01610206) | Linda R Duska | 2012-09-01 |
| Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer (NCT01661868) | Dana-Farber Cancer Institute | 2012-08-01 |
| Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer (NCT01591772) | Memorial Sloan Kettering Cancer Center | 2012-04-24 |
| Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer (NCT01580696) | COL George Peoples, MD, FACS | 2012-04-01 |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer (NCT01493505) | Amgen | 2012-01-01 |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer (NCT01416038) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2011-12-01 |
| Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer (NCT01471483) | Memorial Sloan Kettering Cancer Center | 2011-11-08 |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) (NCT01482715) | pharmaand GmbH | 2011-11-01 |
| A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers (NCT01447706) | Merrimack Pharmaceuticals | 2011-10-01 |
| Pelvic Floor Disorders in Survivors of Gynecologic Malignancies (NCT01370122) | Abramson Cancer Center at Penn Medicine | 2011-05-01 |
| Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive (NCT01262040) | Memorial Sloan Kettering Cancer Center | 2010-12-14 |
| Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission (NCT01248273) | Memorial Sloan Kettering Cancer Center | 2010-11-01 |
| Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer (NCT01248962) | Memorial Sloan Kettering Cancer Center | 2010-11-01 |
| Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (NCT01223235) | Memorial Sloan Kettering Cancer Center | 2010-10-01 |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer (NCT01188876) | Massachusetts General Hospital | 2010-08-01 |
| Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer (NCT01091428) | Millennium Pharmaceuticals, Inc. | 2010-04-16 |
| Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum (NCT01099644) | Y-mAbs Therapeutics | 2010-04-01 |
| Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer (NCT01104675) | CASI pharmaceuticals, Inc. | 2010-04-01 |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies (NCT01065662) | Susana M. Campos, MD | 2010-02-01 |
| Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction (NCT01083537) | University Health Network, Toronto | 2010-02-01 |
| Abraxane/Bevacizumab (NCT01821859) | OHSU Knight Cancer Institute | 2010-01-01 |
| Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT (NCT01276574) | Turku University Hospital | 2009-10-01 |
| Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases (NCT01048814) | Precision Therapeutics | 2009-08-01 |
| Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer (NCT00910000) | Dana-Farber Cancer Institute | 2009-06-01 |
| Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life (NCT00870233) | Memorial Sloan Kettering Cancer Center | 2009-03-24 |
| Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer (NCT00850772) | Queensland Centre for Gynaecological Cancer | 2009-01-01 |
| Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer (NCT00692900) | University of Pittsburgh | 2008-12-01 |
| Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma (NCT00768144) | Dana-Farber Cancer Institute | 2008-09-01 |
| A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT00753480) | Genentech, Inc. | 2008-09-01 |
| Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT00801320) | Beth Israel Deaconess Medical Center | 2008-09-01 |
| Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00634894) | M.D. Anderson Cancer Center | 2008-03-01 |
| A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. (NCT00637390) | University of Michigan Rogel Cancer Center | 2008-03-01 |
| Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin (NCT00652119) | Massachusetts General Hospital | 2008-02-01 |
| A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer (NCT00683241) | Abramson Cancer Center at Penn Medicine | 2007-11-01 |
| PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer (NCT00672295) | AA Secord | 2007-08-01 |
| Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis (NCT00491855) | M.D. Anderson Cancer Center | 2007-06-01 |
| Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT00408070) | UConn Health | 2006-10-01 |
| ChemoFx® PRO - A Post-Market Data Collection Study (NCT00669422) | Precision Therapeutics | 2006-10-01 |
| Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (NCT02349958) | Bay Area Gynecology Oncology | 2006-09-01 |
| Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers (NCT00343044) | Benaroya Research Institute | 2006-06-01 |
| A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer (NCT00281632) | GlaxoSmithKline | 2006-03-01 |
| Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT00267696) | Ohio State University Comprehensive Cancer Center | 2005-11-01 |
| Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer (NCT00230542) | Dana-Farber Cancer Institute | 2005-09-01 |
| Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients (NCT00268918) | Dana-Farber Cancer Institute | 2005-09-01 |
| Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer (NCT00499512) | M.D. Anderson Cancer Center | 2005-08-10 |